About Us

INVENT Pharmaceuticals is developing novel and innovative drugs for the treatment of serious diseases including Cardiometabolic, Cardiopulmonary, Cardiorenal, Fibrosis, Alzheimer's Disease and Psychiatric disorders (ADHD, GAD, MDD), Neuroendocrine Tumors, and SARS-CoV-2. 

We are dedicated to the pursuit of excellence in science to invent safer and highly effective best-in-class and first-in-class small molecule drugs for the treatment of serious, debilitating and life threatening diseases with unmet medical needs.

We design and develop new therapeutics by harnessing the power of leading and cutting-edge science by applying our precision drug design and drug discovery to develop new life-changing medicines to improve, extend, enhance, and save lives of patients living with serious diseases.

We invent small molecule drugs by applying our integrated drug design and discovery platform that includes artificial intelligence and machine learning, our broad and deep knowledge, expertise and capabilities in target selection, precision drug design, medicinal and computational chemistry, site-specific precision deuterium substitution chemistry, and in vitro and in vivo pharmacology.

Our integrated drug discovery platform accelerates the design, discovery and development of innovative and novel, safer and highly effective oral-acting small molecule drugs in multiple therapeutic areas rapidly and highly efficiently in a short period of time due to our dedication, focus, execution, deep and broad experience in precision drug design, discovery and development of novel chemical entities targeting various molecular drug targets including superfamily of G-protein coupled receptors (GPCRs), enzyme, and protein tyrosine kinases. INVENT applies its proprietary drug target-specific integrated precision drug design platform to invent novel, potent, and highly selective and effective drugs.

We are developing novel oral drugs for the treatment of serious prevalent and rare chronic diseases

INVENT Pharma - CVMPR
• Cardiometabolic disease (Obesity/weight reduction)-(Oral GLP-1 Receptor Agonist)
• Cardiopulmonary- Pulmonary Arterial Hypertension (PAH)
• Cardiorenal- Chronic Kidney Disease (CKD)
• Liver Fibrosis
• Small-Intestine Neuroendocrine Tumors (SI-NET)

INVENT Neuro
• Alzheimer's Disease (AD)
• Cognitive Impairment Associated with Schizophrenia (CIAS)
• Attention-Deficit Hyperactivity Disorder (ADHD)
• General Anxiety Disorders (GAD)
• Post Traumatic Stress Disorder (PTSD)
• Major Depressive Disorders (MDD)

INVENT Antivirals
• SARS-CoV-2: Deuterated-Nirmatrelvir